#USA #Minneapolis #medical technology #FLEX Vessel Prep #Flex Vascular

Exciting Updates from FLEX Vascular's Recent Clinical Study

FLEX Vascular, a prominent medical technology company based in Minneapolis, has made headlines by revealing groundbreaking findings from its FLEX FIRST AV Registry. This prospective, multi-center clinical study aimed to assess the effectiveness and safety of the FLEX™ Vessel Prep System in patients facing dysfunctional hemodialysis access. The results were presented on April 21, 2026, at the esteemed Charing Cross (CX) Symposium in London, England. Lead investigator Dr. Ari Kramer, who chairs the Vascular Access Program at Spartanburg Regional Medical Center, South Carolina, shared the compelling data derived from the study.

Overview of the Study

The FLEX FIRST AV Registry involved 130 patients treated across four different centers in the United States. It showcased a diverse and high-risk patient population representative of real-world clinical environments. The findings indicated a remarkable blend of safety, durability, and performance when utilizing the FLEX™ Vessel Prep System on complex vascular lesions.

Key Findings at 12 Months

The results highlighted several significant milestones:

• - Zero Severe Adverse Events (SAE): Within the first 30 days following the procedure, no serious complications were reported, with only a minor 0.8% rate of complications overall.
• - 40% Primary Patency: For target lesions, the study reported a primary patency rate after 12 months that nearly doubled previous benchmarks for PTA.
• - 100% Secondary Patency: Remarkably, all AV grafts maintained patency after a year, with no accesses abandoned, demonstrating the efficacy of the FLEX system in sustained treatment.
• - Reduced Procedures: Incorporating FLEX with PTA indicated an average of one less intervention required per patient annually.

Dr. Ari Kramer remarked, “These results signify a transformative shift in how we approach AV access interventions. In real-world applications, we're seeing outstanding safety rates, diminished re-interventions, and encouraging durability even in challenging cases.”

Real-World Evidence for Clinical Practice

The study's population exhibited critical comorbidities, with 64.6% having diabetes and a staggering 95.4% suffering from hypertension. Furthermore, the demographic composition included 60% African American participants, enhancing the applicability of the findings to diverse patient care scenarios.

Introduction of a New Approach

The FLEX™ Vessel Prep System stands out by employing a groundbreaking technique known as Kinetic Endovascular Micro-Incision Creation (KEMIC). This device operates without drugs or implants, focusing on optimizing vessel compliance prior to standard angioplasty procedures.

Dr. Jordan Knepper, Chief Medical Officer of FLEX Vascular, elaborated on the significance of these findings: “Together, these results bolster a new care paradigm in access interventions, defined by enhanced safety, reduced re-interventions, and long-lasting outcomes without added procedural complexity.”

About FLEX Vascular

Founded under the VentureMed Group, Inc., FLEX Vascular is at the forefront of innovating endovascular solutions designed specifically for arteriovenous access and peripheral vessel interventions. Their flagship product, the FLEX Vessel Prep™ System, has received FDA 510(k) clearance and CE mark approval to facilitate robust vessel preparation through its proprietary KEMIC technology.

In conclusion, FLEX Vascular's latest results underline the efficiency and potential of their Vessel Prep System, heralding a promising direction for ongoing vascular access interventions in clinical settings. As technologies evolve, so too does the landscape of medical procedures — with companies like FLEX leading the charge toward improved patient outcomes.